The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
 
Ahmed Omar Kaseb
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Bayer Health; Bristol-Myers Squibb; Exelixis; Merck
Consulting or Advisory Role - Bayer Health; Bristol-Myers Squibb; Exelixis; Merck
Research Funding - Bayer/Onyx; Bristol-Myers Squibb; Genentech; Merck
Travel, Accommodations, Expenses - Bayer/Onyx; Bristol-Myers Squibb; Exelixis; Merck
 
Roberto Carmagnani Pestana
No Relationships to Disclose
 
Luis M. Vence
No Relationships to Disclose
 
Jorge M. Blando
No Relationships to Disclose
 
Shalini Singh
No Relationships to Disclose
 
Naruhiko Ikoma
No Relationships to Disclose
 
Jean-Nicolas Vauthey
No Relationships to Disclose
 
James Patrick Allison
Patents, Royalties, Other Intellectual Property - Inventor of a patent held by the University of California, Berkeley, and licensed to Bristol Meyers-Squibb; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Padmanee Sharma
Stock and Other Ownership Interests - BioAtla; Constellation Pharmaceuticals; Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics
Consulting or Advisory Role - Amgen; Amgen (I); Astellas Pharma; AstraZeneca; AstraZeneca (I); BioAtla; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Merck Sharp & Dohme; Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)